Chemotherapy for Metastatic Head and Neck Squamous Cell Carcinomas
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".
Deadline for manuscript submissions: 15 July 2026 | Viewed by 48
Special Issue Editor
Special Issue Information
Dear Colleagues,
The outcomes of systemic therapy for head and neck squamous cell carcinomas (HNSCCs) have significantly progressed with the advent of molecular target agents and immune checkpoint inhibitors (ICIs). However, new challenges have emerged, including overcoming ICI resistance and formulating secondary treatment strategies. The development of biomarkers for predicting drug sensitivity is also gaining increasing attention. This Special Issue aims to provide innovative ideas and insights regarding the enhancement of treatment outcomes in systemic therapy for metastatic HNSCCs.
In this Special Issue, we invite discussions on various topics related to systemic therapy for metastatic HNSCCs. These include translational research investigating underlying mechanisms and pathology to determine drug sensitivity and prognosis.
The purpose of this Special Issue is to present new insights into optimized treatment strategies for metastatic HNSCCs.
We welcome reviews and original research articles for this Special Issue, with submissions due by 15 July 2026.
We look forward to your contributions.
Dr. Ken Saijo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- head and neck squamous cell carcinomas
- HNSCC
- immune checkpoint inhibitor
- biomarker
- chemotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
